Buried in the FY 2027 inpatient rule CMS published on August 4: the repeal of the alternative pathway that let an FDA Breakthrough Device designation stand in for proof of substantial clinical improvement when applying for a New Technology Add-on Payment. That reads like paperwork; it is a pricing constraint. Medicare pays one fixed amount per inpatient stay, set by the stay's MS‑DRG, regardless of what the hospital spent — so every dot here is one of the 773 national MS‑DRGs, average Medicare payment against annual discharges, and the slider is the cost of the new thing you want to put inside that stay. At $25,000 with no add-on payment, the technology costs more than the entire average Medicare payment in 620 of 773 DRGs — 6.09 million discharges, 88% of all Medicare fee-for-service inpatient volume. Turn NTAP on at 65% and the underwater count falls to 220 DRGs and 2.22 million discharges. That gap, 620 versus 220, is the add-on payment. The rule didn't remove NTAP; it removed the shortcut to qualifying for it, for applications submitted on or after October 1, 2026. Stress test: flip the axis toggle to Charges and the red mostly disappears — at a $50,000 technology only 196 DRGs sit below the line by charges against 729 by payments, because the median DRG's submitted charge is 6.0× its Medicare payment, which is why a market model built off chargemaster data invents roughly four times the headroom that exists. And drag min annual discharges up: 729 underwater becomes 482 at 1,000/yr and 243 at 5,000/yr, because 263 of the 773 DRGs see fewer than 1,000 discharges nationally and together carry 1.6% of volume. Critical lens: NTAP is calculated off the hospital's cost for the case, and this file contains payments and charges and no cost column at all — so the red-dot test is a ceiling test, not a margin test.
Data explorer
On July 8, FDA and CMS officials hosted an unannounced “clinical AI demo day” at White Oak; STAT reviewed the agenda and published it August 5. Ten companies, no health system, no specialty society — and the agenda covered not only whether the tools are safe but how Medicare should pay for them. This is that second question, drawn. One animated field, no click-through: it plays itself and you can scrub back. All 773 national MS‑DRGs arrive as a scattered cloud, settle into a dot histogram sorted by what Medicare actually pays, the median line lands at $12,714, and then a technology-cost line sweeps in from $300,000 down to $25,000 while the dots it can no longer fit inside turn red and a live counter runs. At $25,000 with no add-on payment that is 620 of 773 prices and 88% of all Medicare fee-for-service inpatient volume; with NTAP at 65% it is 220 and 32%. Then the last act: an empty box where autonomous clinical AI would sit — no DRG, no code, no rate, 0 of 773 rungs — because when no clinician performs the service, no existing payment category contains it, and whoever defines “a unit of service” sets the business model for the whole category. Sliders hand control back after the story ends. Critical lens: these are payments, not costs, and NTAP is computed off costs, so the red is a ceiling test not a margin test; fee-for-service only, so Medicare Advantage — roughly half of enrollees — is absent; and 263 of the 773 DRGs see under 1,000 discharges a year and carry 1.6% of volume, so a dot is a row, not a population.
Graphical narrative